Home » Stocks » PLX

Protalix BioTherapeutics, Inc. (PLX)

Stock Price: $2.17 USD 0.07 (3.33%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 98.48M
Revenue (ttm) 52.57M
Net Income (ttm) -13.67M
Shares Out 45.38M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE 111.11
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $2.17
Previous Close $2.10
Change ($) 0.07
Change (%) 3.33%
Day's Open 2.14
Day's Range 2.10 - 2.19
Day's Volume 2,605,216
52-Week Range 2.00 - 7.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, June 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors are advise...

1 week ago - PRNewsWire

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Farmaceutici S.p.A. have provided an update on the clinical development of pegunigalsidase alfa (PRX–102) for the proposed treatment of Fabry disease.

1 week ago - Benzinga

CARMIEL, Israel and BOSTON, June 2, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercia...

1 week ago - PRNewsWire

CARMIEL, Israel, May 14, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

4 weeks ago - PRNewsWire

On Friday, May 14, Protalix BioTherapeutics (AMEX:PLX) will release its latest earnings report. Here is Benzinga's outlook for the company.

1 month ago - Benzinga

CARMIEL, Israel, May 7, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...

1 month ago - PRNewsWire

Investors did not like the company's latest regulatory update.

1 month ago - The Motley Fool

CARMIEL, Israel, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization o...

1 month ago - PRNewsWire

An update from Protalix BioTherapeutics shows how a disappointing FDA decision can roil a biotech name like PLX stock. The post PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today appeared fir...

1 month ago - InvestorPlace

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici, have received a Complete Response Letter (CRL) from the FDA related to the marketing app...

1 month ago - Benzinga

CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercia...

1 month ago - PRNewsWire

CARMIEL, Israel, March 30, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

2 months ago - PRNewsWire

CARMIEL, Israel, March 22, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization ...

2 months ago - PRNewsWire

CARMIEL, Israel, March 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

3 months ago - PRNewsWire

Protalix BioTherapeutics Inc (NYSE: PLX) and its collaborating partner Chiesi Farmaceutici S.p.A. announced positive topline results from the BRIGHT Phase 3 trial evaluating pegunigalsidase alfa (PRX–10...

3 months ago - Benzinga

CARMIEL, Israel, Feb. 18, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

3 months ago - PRNewsWire

Protalix BioTherapeutics Inc (NYSE: PLX) prices the previously announced underwritten public offering of 7.6 million shares at $4.60 per share, a discount of around 21% on the last close of $5.79 on Thu...

4 months ago - Benzinga

CARMIEL, Israel, Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the "Company"), a biopharmaceutical company focused on the development, production and comm...

4 months ago - PRNewsWire

CARMIEL, Israel, Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

4 months ago - PRNewsWire

Protalix BioTherapeutics Inc (NYSE: PLX) has announced an exclusive worldwide license agreement with SarcoMed USA Inc for alidornase alfa, also known as PRX–110, for use in the treatment of any human re...

4 months ago - Benzinga

CARMIEL, Israel, Feb. 11, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development production and commercialization of...

4 months ago - PRNewsWire

CARMIEL, Israel, and BOSTON, Feb. 10, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerc...

4 months ago - PRNewsWire

CARMIEL, Israel, Feb. 1, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

4 months ago - PRNewsWire

CARMIEL, Israel, Jan. 4, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

5 months ago - PRNewsWire

CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

5 months ago - PRNewsWire

CARMIEL, Israel and BOSTON, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercial...

5 months ago - PRNewsWire

Protalix had a PDUFA date for Fabry Disease drug PRX-102 on January 27, now postponed to April 27. The postponement seems only procedural and strictly Covid related, as the accelerated approval timeline...

5 months ago - Seeking Alpha

CARMIEL, Israel, Nov. 27, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

6 months ago - PRNewsWire

CARMIEL, Israel, Nov. 5, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of r...

7 months ago - PRNewsWire

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

CARMIEL, Israel, Oct. 29, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

7 months ago - PRNewsWire

CARMIEL, Israel, Oct. 29, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

7 months ago - PRNewsWire

CARMIEL, Israel, Oct. 26, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

7 months ago - PRNewsWire

BOSTON and CARMIEL, Israel, Oct. 2, 2020 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), an...

8 months ago - PRNewsWire

Protalix Could Claim Substantial Global Market Share In Fabry Disease

8 months ago - Seeking Alpha

CARMIEL, Israel, Sept. 8, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

9 months ago - PRNewsWire

Protalix shares have gone nowhere since June.

9 months ago - Seeking Alpha

CARMIEL, Israel,, Aug. 24, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

9 months ago - PRNewsWire

CARMIEL, Israel, Aug. 11, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

10 months ago - PRNewsWire

Protalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

CARMIEL, Israel, Aug. 6, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc.

10 months ago - PRNewsWire

CARMIEL, Israel, Aug. 3, 2020 /PRNewswire/Protalix BioTherapeutics, Inc.

10 months ago - PRNewsWire

CARMIEL, Israel, July 23, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

10 months ago - PRNewsWire

Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant

1 year ago - Seeking Alpha

Protalix Should Go Higher If FDA Approves Fabry Disease Therapy

1 year ago - Seeking Alpha

Protalix Bio Therapeutics (PLX) CEO, Dror Bashan on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

1 year ago - Zacks Investment Research

Protalix BioTherapeutics' (PLX) CEO Dror Bashan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

1 year ago - Zacks Investment Research

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form... [Read more...]

Industry
Biotechnology
IPO Date
May 15, 1998
CEO
Dror Bashan
Employees
207
Stock Exchange
NYSEAMERICAN
Ticker Symbol
PLX
Full Company Profile

Financial Performance

In 2020, PLX's revenue was $62.90 million, an increase of 15.00% compared to the previous year's $54.69 million. Losses were -$6.52 million, -64.31% less than in 2019.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for PLX stock is "Buy" and the 12-month stock price forecast is 9.75.

Price Target
$9.75
Analyst Consensus: Buy